JAN

Apr 06, 2016

Janssen Biotech, Inc. has announced that it has entered a worldwide collaboration and license agreement with TESARO, Inc. for exclusive rights to the investigational compound niraparib in prostate cancer, which is an orally administered poly polymerase (PARP) inhibitor. Nirparib is currently in late-stage development for patients with ovarian cancer and metastatic breast cancer.

As per the terms of the collaboration arrangement and license agreement, Janssen will have global rights and be responsible for all commercialization activities and development for niraparib for use in prostate cancer, except in Japan. TESARO will maintain global development, commercial rights and manufacturing for all other indications.

“PARP inhibitors are an exciting, emerging class of medicines in prostate cancer, and we believe niraparib will perfectly complement our existing portfolio. Our team is eager to apply its prostate cancer expertise to niraparib, and enthusiastic about its potential to expand our impact on the lives of men with this disease,” said Peter F. Lebowitz, M.D., Ph.D., Oncology Therapeutic Area Head, Janssen Research & Development, LLC.

The proteins of PARP play a key survival role in DNA repair in cancer cells. By preventing PARP, certain defective cancer cells are not capable of repairing themselves, which leads toward cell death. Some men with prostate cancer have these defective cancer cells and may get benefits from using a PARP inhibitor, either alone, or in combination with other treatments.

2 thoughts on “Janssen Collaborates with TESARO, Inc., for Niraparib in Prostate Cancer

Leave a Reply